Replies to post #68035 on Avid Bioservices Inc (CDMO)

[geocappy1]

Maybe I agree and maybe I don't. If the idea is to go it alone maybe we just take our best shot with Bavi on the one indication we think is best and take it thru phase III and on to market. Spend as little money as possible til we know it works. Save our money and the dilution.

However, if the idea is to partner big or sell the company outright then I would think if we have a hunch the science works then we want to get as many indications covered as we can stomach spending money on. That way when and if one indication gets along far enough that there is no longer any doubt about the science, a partner or buyer is willing to pay a whole lot more because we have several indications at or thru the phaseIIs making the company worth a whole lot more.

Frustrated, you do not have to believe our management team is going to get it done, however, you can agree that the above makes sense.

[keep_trying]

Frustrated, Jay is now working with Amy on PRs, so that may help fortify their communications to better answer to technical questions, IMO.

What do I make of the financing? The nation is trying to recover from what has been termed the "Great Recession" and the President just announced a hardship plan to give relief for jobs creation and payrolls by cutting social security taxes at a time when balance of payments for social security solvency is already an issue. During the Great Recession, the financial system melted down to the extent that the cash reserves in my 401(k) had a hold put on them for over six months while supposedly solid funds scrounged for cash and restructured their reserves, leaning on government and central bank assistance. What should have been cash on hand for me to invest in depressed stocks after the 2008 pps dip was sequestered for use by the same third parties that contributed to the extent of that dip, which in my perspective, is unprecedented for investing that I have been engaging since the 1980s.

Through all that, PPHM has managed to progress trials for their primary products, Cotara and the Bavituximab family while retaining intellectual property rights. Plus, PPHM has managed to keep enough cash in their coffers to fund an expanded payroll that includes some of the best names in the industry for developing new pharma treatments. Cash reserves, considering the latest financing, keeps PPHM at about par with what they had at the end of the last quarter, despite increased outlays for trials, within a few million. Funds on paper should carry PPHM through the end of their fiscal year 2012 (April 30, 2012) and additional fund raising should extend that beyond. Preliminary results from ongoing trials of high interest should be reporting in around the end of the year and PPHM has an FDA meeting scheduled to assess trials and approvals.

Let's listen to the PPHM earnings call, due to start in a half hour, and see what questions PPHM answers for us without a need for emailing investor relations.

Best wishes and IMO.
KT